This indicator shows the number and percent of people with diabetes receiving sulfonylureas (glibenclamide, gliclazide and glipizide) regularly. Regular use was defined as sulfonylureas dispensed in three or more quarters in a year.
Understanding variation in dispensing these medicines is important for optimising diabetes care and ensuring that patients receive the most appropriate treatments.
People with diabetes dispensed sulfonylureas in three or four quarters in the relevant year.
Numerator detail
Medications: 156702 glibenclamide
156801 gliclazide
156901 glipizide
Count of distinct master NHIs identified as having diabetes as per the VDR
Disaggregation
For single map analysis: By year (2018‒22), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other) and Health New Zealand district of domicile.
For PHO analysis: By year (2022), age group (0‒14 years, 15‒24 years, 25‒44 years, 45‒64 years, 65‒74 years and 75+ years), gender (female and male), ethnic group (Māori, Pacific peoples, Indian and European/other), PHO most recently enrolled with (for the relevant year), PHO group (small, medium, medium‒large and large).
- Data is not presented where the number of people in the numerator was less than 10. This is to preserve confidentiality.
- Ethnicity data presented is prioritised ethnic group (Māori, Pacific peoples, Indian and European/other).
- For all indicators, individuals with missing values for any of the variables of interest (age, gender, ethnicity and district) are excluded completely. For instance, if there are any missing values for age, they are excluded from all analyses. This approach ensures a consistent denominator throughout the analyses.
- Demographic information is taken from the VDR.
Exclusions
- People who died during the year
- People not enrolled in a PHO